COMPARE
BPC-157, GHK-Cu and KPV side by side
Three peptides, one repair theme, three very different positions in the evidence landscape.
The short version
This page puts the three research peptides covered on this desk next to each other so you can read their similarities and differences at a glance. They share a thematic home — all three have been studied in contexts involving tissue repair, inflammation, or matrix biology — but they are structurally distinct, mechanistically separate, and occupy very different positions in terms of how much human evidence exists and what their regulatory status is. GHK-Cu has the most human data, is a legal cosmetic ingredient as a topical, and has clinical-study evidence for skin outcomes. BPC-157 has the broadest animal-model track record but almost no human data and restricted regulatory status. KPV is entirely preclinical.
Comparison table
| Feature | BPC-157 | GHK-Cu | KPV |
|---|---|---|---|
| Full name | Body Protection Compound 157 | Glycyl-L-Histidyl-L-Lysine Copper(II) complex | Lysine-Proline-Valine (alpha-MSH C-terminal tripeptide) |
| Class | Stable gastric pentadecapeptide | Copper-binding tripeptide (cosmetic ingredient / research peptide) | Melanocortin-derived anti-inflammatory tripeptide |
| Primary mechanism studied | Pro-angiogenic (VEGFR2-Akt-eNOS); cytoprotective | Fibroblast collagen/elastin synthesis; matrix remodeling; copper chaperone | NF-kB + MAP-kinase suppression; PepT1-mediated gut uptake |
| Best-studied tissue context | Tendon, gut, muscle, vascular (animal models) | Skin and connective tissue (topical, human + animal) | Gut mucosa (murine colitis models) |
| Species with most evidence | Rats and mice | Human (topical), rats, in vitro | Mice, in vitro (human cell lines) |
| Human evidence | 2 pilot safety reports (2025); no controlled efficacy trials | Small controlled topical skin trials; one 45-patient RCT for hair growth | None — entirely preclinical |
| Evidence maturity | Broad preclinical; early human | Modest human (topical only); broad preclinical | Preclinical only |
| FDA status | Not approved; placed in 503A non-compoundable category (2023) | Topical Copper Tripeptide-1 = legal cosmetic ingredient; injectable/systemic = unapproved research chemical | Not approved; research chemical only |
| WADA status | Prohibited at all times (S0 — non-approved substances) | Not currently listed (verify current list) | Not specifically listed; caution advised in sport context |
| Topical / cosmetic use | Not typical | Yes — well-established cosmetic ingredient | Not typical |
Reading this table
A few things stand out when these three are placed beside each other.
Evidence asymmetry is striking. GHK-Cu has controlled human trial data for skin and hair outcomes; BPC-157 has two safety pilot reports; KPV has none. That gradient matters when reading claims about any of the three — the human support behind skin GHK-Cu is categorically stronger than what exists for the others, though it is still limited to small trials with topical endpoints.
Mechanism and target tissue are complementary, not redundant. BPC-157 enters damaged tissue from the vascular side (new blood vessels). GHK-Cu works on the extracellular scaffolding (collagen, elastin). KPV works on the inflammatory signaling that governs the early repair environment. They describe repair from three angles rather than doing the same thing three ways. This is why they sit together on a recovery-and-repair desk.
Regulatory situations diverge. GHK-Cu as a topical cosmetic ingredient has a settled, legal status for surface skin use. BPC-157 has an explicitly restricted status in US pharmacy compounding and is prohibited in sport. KPV is a research chemical with no approved use, though WADA has not placed it by name on the prohibited list.
For the full cited account of any single compound, use the individual pages: BPC-157, GHK-Cu, KPV.